Breaking News, Financial News

Financial Report: Hospira

Quality and product related charges contribute to losses

Hospira

1Q Revenues: $884.0 million (-9%)

1Q Loss: $76.6 million (earnings were $40.2 million 1Q12)

Comments: Specialty Injectable Pharmaceuticals sales were $651.5 million, up 11%. Medication Management revenues dropped 51% to $124.5 million. Other Pharma sales were $108.0 million, down 12%. Certain quality and product related charges primarily include third party oversight and consulting costs, extended production downtime related costs, failure to supply penalties, device product review and remediation costs to address identified issues, and costs for corrective actions including product recalls.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters